Abstract
Since the first Zika virus (ZIKV) infection was confirmed in Brazil in May 2015, several hundred thousand cases have been reported across the Americas. This figure gives an incomplete picture of the epidemic, however, given that asymptomatic infections, imperfect surveillance, and variability in reporting rates imply that the incidence of infection was likely much higher. The infection attack rate (IAR)—defined as the proportion of the population that was infected over the course of the epidemic—has important implications for the longer-term epidemiology of Zika in the region, such as the timing, location, and likelihood of future outbreaks. To estimate the IAR and the total number of people infected, we leveraged multiple types of Zika case data from 15 countries and territories where subnational data were publicly available. Datasets included confirmed and suspected Zika cases in pregnant women and in the total population, Zika-associated Guillan-Barré syndrome cases, and cases of congenital Zika syndrome. We used a hierarchical Bayesian model with empirically-informed priors that leveraged the different case report types to simultaneously estimate national and subnational reporting rates, the fraction of symptomatic infections, and subnational IARs. In these 15 countries and territories, estimates of Zika IAR ranged from 0.084 (95% CrI: 0.067 − 0.096) in Peru to 0.361 (95% CrI: 0.214 − 0.514) in Ecuador, with significant subnational variability in IAR for every country. Totaling these infection estimates across these and 33 other countries and territories in the region, our results suggest that 132.3 million (95% CrI: 111.3-170.2 million) people in the Americas have been infected by ZIKV since 2015. These estimates represent the most extensive attempt to date to determine the size of the Zika epidemic in the Americas, and they offer an important baseline for assessing the risk of future Zika epidemics in this region.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by NIH supplement Grant R01 AI102939-05 and a RAPID grant from the National Science Foundation (DEB 1641130). TAP, SMM, ASS, KJS, and RJO also acknowledge support from a DARPA Young Faculty Award (D16AP00114).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.